JP2020522697A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522697A5 JP2020522697A5 JP2019566358A JP2019566358A JP2020522697A5 JP 2020522697 A5 JP2020522697 A5 JP 2020522697A5 JP 2019566358 A JP2019566358 A JP 2019566358A JP 2019566358 A JP2019566358 A JP 2019566358A JP 2020522697 A5 JP2020522697 A5 JP 2020522697A5
- Authority
- JP
- Japan
- Prior art keywords
- ctc
- biomarker
- cancer
- aspects
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 74
- 210000004027 cell Anatomy 0.000 description 40
- 206010028980 Neoplasm Diseases 0.000 description 32
- 239000000090 biomarker Substances 0.000 description 32
- 201000011510 cancer Diseases 0.000 description 32
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 30
- 206010060862 Prostate cancer Diseases 0.000 description 20
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 20
- 229960004671 enzalutamide Drugs 0.000 description 12
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- 238000003125 immunofluorescent labeling Methods 0.000 description 10
- 230000000877 morphologic effect Effects 0.000 description 10
- 230000007170 pathology Effects 0.000 description 9
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023086656A JP2023120213A (ja) | 2017-06-02 | 2023-05-26 | 転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514642P | 2017-06-02 | 2017-06-02 | |
| US62/514,642 | 2017-06-02 | ||
| US201762531725P | 2017-07-12 | 2017-07-12 | |
| US62/531,725 | 2017-07-12 | ||
| PCT/US2018/035581 WO2018222979A1 (en) | 2017-06-02 | 2018-06-01 | Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023086656A Division JP2023120213A (ja) | 2017-06-02 | 2023-05-26 | 転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522697A JP2020522697A (ja) | 2020-07-30 |
| JP2020522697A5 true JP2020522697A5 (https=) | 2021-07-26 |
Family
ID=64455086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566358A Pending JP2020522697A (ja) | 2017-06-02 | 2018-06-01 | 転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法 |
| JP2023086656A Pending JP2023120213A (ja) | 2017-06-02 | 2023-05-26 | 転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023086656A Pending JP2023120213A (ja) | 2017-06-02 | 2023-05-26 | 転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220260574A1 (https=) |
| EP (1) | EP3631445B1 (https=) |
| JP (2) | JP2020522697A (https=) |
| CN (1) | CN110998318A (https=) |
| AU (1) | AU2018275265A1 (https=) |
| CA (1) | CA3065316A1 (https=) |
| IL (1) | IL270974A (https=) |
| WO (1) | WO2018222979A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020225753A2 (en) * | 2019-05-06 | 2020-11-12 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| EP3969978B1 (en) | 2019-05-14 | 2025-10-01 | University of Pittsburgh - of the Commonwealth System of Higher Education | System and method for characterizing cellular phenotypic diversity from multi-parameter cellular. and sub-cellular imaging data |
| WO2021108043A1 (en) * | 2019-11-27 | 2021-06-03 | University Of Cincinnati | Assessing treatment response with estimated number of tumor cells |
| AU2021207312A1 (en) * | 2020-01-17 | 2022-06-30 | Universität Zürich | Single cell pathology analysis of tumour samples |
| CN114092934A (zh) * | 2020-07-31 | 2022-02-25 | 骏实生物科技(上海)有限公司 | 循环肿瘤细胞的分类方法 |
| CN114594252A (zh) * | 2020-12-03 | 2022-06-07 | 复旦大学附属中山医院 | 循环肿瘤细胞形态学特征在胃癌临床诊疗中的应用 |
| JP7836038B2 (ja) * | 2020-12-10 | 2026-03-26 | 国立大学法人信州大学 | メラノーマ患者の治療効果を判定する方法 |
| WO2022132917A1 (en) * | 2020-12-15 | 2022-06-23 | Carnegie Mellon University | System, method, and computer program product for classification of diseases based on expansion microscopic images |
| EP4060319A1 (en) | 2021-03-12 | 2022-09-21 | Sysmex Corporation | Analysis method and analyzer |
| JP7824031B2 (ja) * | 2021-03-12 | 2026-03-04 | シスメックス株式会社 | 分析方法および分析装置 |
| US11735303B2 (en) * | 2021-06-22 | 2023-08-22 | David Haase | Apparatus and method for determining a composition of a replacement therapy treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105636594A (zh) * | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物 |
| WO2015048740A1 (en) * | 2013-09-30 | 2015-04-02 | The Scripps Research Institute | Genotypic and phenotypic analysis of circulating tumor cells to monitor tumor evolution in prostate cancer patients |
| US10527624B2 (en) * | 2014-01-27 | 2020-01-07 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| US20150212089A1 (en) * | 2014-01-30 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
| CA2959336A1 (en) * | 2014-08-25 | 2016-03-03 | The Johns Hopkins University | Methods and compositions related to prostate cancer therapeutics |
| US20180155794A1 (en) * | 2015-05-29 | 2018-06-07 | Epic Sciences, Inc. | Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc) |
-
2018
- 2018-06-01 US US16/617,423 patent/US20220260574A1/en not_active Abandoned
- 2018-06-01 CN CN201880050607.7A patent/CN110998318A/zh active Pending
- 2018-06-01 EP EP18810303.0A patent/EP3631445B1/en active Active
- 2018-06-01 JP JP2019566358A patent/JP2020522697A/ja active Pending
- 2018-06-01 WO PCT/US2018/035581 patent/WO2018222979A1/en not_active Ceased
- 2018-06-01 CA CA3065316A patent/CA3065316A1/en active Pending
- 2018-06-01 AU AU2018275265A patent/AU2018275265A1/en not_active Abandoned
-
2019
- 2019-11-27 IL IL270974A patent/IL270974A/en unknown
-
2023
- 2023-05-26 JP JP2023086656A patent/JP2023120213A/ja active Pending
-
2024
- 2024-06-18 US US18/746,816 patent/US20250155440A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522697A5 (https=) | ||
| Castro-Giner et al. | Tracking cancer progression: from circulating tumor cells to metastasis | |
| Li et al. | CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma | |
| JP7692075B2 (ja) | 循環細胞を用いて被検者における治療反応及び疾患の進行をモニターする方法 | |
| CN104975063B (zh) | 抗肿瘤药物生物标志物的筛选方法及其应用 | |
| Bork et al. | Prognostic relevance of minimal residual disease in colorectal cancer | |
| Lazar et al. | Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line | |
| Tang et al. | Blood‐based biopsies—Clinical utility beyond circulating tumor cells | |
| Mansilla et al. | The identification and isolation of CTCs: a biological Rubik’s cube | |
| Ross et al. | The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer | |
| Kiss et al. | Correlation between disease stage and the presence of viable circulating tumor cells in endometrial cancer | |
| Rozova et al. | Machine learning reveals mesenchymal breast carcinoma cell adaptation in response to matrix stiffness | |
| Wu et al. | Advances in the biology, detection techniques, and clinical applications of circulating tumor cells | |
| M Saini et al. | A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer | |
| Bou Zerdan et al. | Liquid biopsies and minimal residual disease in lymphoid malignancies | |
| Wenta et al. | Measurable morphological features of single circulating tumor cells in selected solid tumors—a pilot study | |
| Jamin et al. | Combined RNA/tissue profiling identifies novel cancer/testis genes | |
| Yu et al. | Analyzing circulating tumor cells and epithelial-mesenchymal transition status of papillary thyroid carcinoma patients following thyroidectomy: a prospective cohort study | |
| WO2019037106A1 (zh) | 用于评价乙肝肝病nk细胞功能的实用性模型的构建方法 | |
| Schwalie et al. | Single-cell characterization of menstrual fluid at homeostasis and in endometriosis | |
| Hamon et al. | TREM2 macrophages are associated with enhanced response to PD-1 blockade in human hepatocellular carcinoma | |
| Wark et al. | Dynamics of three-dimensional telomere profiles of circulating tumor cells in patients with high-risk prostate cancer who are undergoing androgen deprivation and radiation therapies | |
| JP2018535432A5 (https=) | ||
| Heckenbach et al. | Deep learning shows cellular senescence is a barrier to cancer development | |
| Podaza et al. | Novel co-culture strategies of tumor organoids with autologous T-cells reveal clinically relevant combinations of immune-checkpoint and targeted therapies |